Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 6/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.39 |
| ▸ | BTK | Q06187 | 6/20 | 0.39 |
| ▸ | CDC7 | O00311 | 1/20 | 0.39 |
| ▸ | PIM1 | P11309 | 1/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.37 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.37 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.37 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27378023 | 0.91 | PIM1 (0.38) | PARP1AURKARPS6KB1BTKCDC7 | |
| SCHEMBL29326232 | 0.84 | KDM4E (0.43) | HSP90AA1ITGA4ITGB7 | |
| SCHEMBL29326338 | 0.84 | BTK (0.42) | AURKARPS6KB1BTKKCNMA1ITGA4 | |
| SCHEMBL29326278 | 0.84 | AURKA (0.40) | AURKAITGA4ITGB7 | |
| SCHEMBL29326228 | 0.82 | PLK4 (0.41) | PARP1PIM1KCNMA1ITGA4ITGB7 | |
| SCHEMBL29326351 | 0.82 | MCL1 (0.39) | PIM1ITGA4ITGB7 | |
| SCHEMBL27192156 | 0.77 | FEN1 (0.39) | AURKARPS6KB1BTKKCNMA1 | |
| SCHEMBL29326345 | 0.77 | BTK (0.43) | PARP1BTKITGA4ITGB7 | |
| SCHEMBL29326170 | 0.77 | ERCC5 (0.42) | AURKARPS6KB1BTKITGA4ITGB7 | |
| SCHEMBL27377611 | 0.74 | KDM4E (0.42) | HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239807-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239807-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | ACE2, TMPRSS2, ACE | PARP1 1376/4885AURKA 3698/4885RPS6KB1 2815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.